A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

Phase 4 Completed 33 enrolled Janssen Cilag N.V./S.A.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the outcome of medication discontinuation, the safety and effectiveness of re-initiating risperidone long acting injection (RLAI) in case of relapse (the return of a medical problem) of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) during the study observation period of 36 months.

Timeline

Start: 2006-04
Primary completion: 2010-03
Completion: 2010-03

Publications

Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez G. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study. J Clin Psychiatry. 2012 Apr;73(4):e541-7. doi: 10.4088/JCP.11m07138.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Risperidone	Other / unclassified	1 mg	Oral
Subject	Risperidone	Other / unclassified	2 mg	Oral
Subject	Risperidone	Other / unclassified	3 mg	Oral
Subject	Risperidone	Other / unclassified	25 mg	Oral
Subject	Risperidone	Other / unclassified	37.5 mg	Oral
Subject	Risperidone	Other / unclassified	50 mg	Oral

A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode

Summary

Timeline

Publications

Drugs

Indications